ALKERMES | ALKS - Net Income



ALKERMES reported $87.1M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
ALKERMES USD 87.1M 64.63M Jun/2025
Amgen USD 1.43B 298M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
J&J USD 5.54B 5.46B Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Merck USD 4.43B 652M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Otsuka Holdings JPY 88.53B 3.53B Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025